It was created on the basis of polygalacturonic acid (pectin) and anti-tuberculosis drugs – isoniazid, ethambutol and rifampicin.

According to the Academy of Sciences, unlike its predecessors, the new drug has a low level of side effects and lasts longer in the body.

Its main advantage is its macromolecular nature. By chemical bonds, it combines with anti-tuberculosis drugs.

The substance that is part of Biomayrin purposefully affects pathogenic cells. The drug has a high activity against various strains of tuberculosis.